{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "SIBN",
  "name": "SI-BONE, Inc.",
  "url": "https://frontierpicks.com/dossiers/SIBN/",
  "json_url": "https://frontierpicks.com/dossiers/SIBN.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "The 2026-08-03 binary resolved bullish: Q2 revenue $56.01M (+15.2% YoY vs +11.2% in Q1), EPS −$0.09 vs −$0.15 est, FY26 floor raised to $231M, three target hikes on 2026-08-04. Price cleared the $17.05 shelf that capped June–July. Spinopelvic-expansion narrative accelerating, but RSI 72 at the 2026-08-14 close of $18.93 and no dated catalyst until the Q3 print (~November).",
  "invalidation_trigger": "A weekly close below $17 surrenders the $17.05 shelf reclaimed after the 2026-08-03 Q2 print and puts price back in the $14.13–$17.05 June–July range; secondarily, a Q3 print (est. ~2026-11-02) worse than the guided 1–2% sequential decline, or any trim to the $231–233M FY2026 guide.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Still GAAP loss-making: Q2 2026 net loss $4.1M. The profitability case rests on adjusted EBITDA ($2.8M in Q2) and a guided 2026 free-cash-flow crossover.",
    "Pelvic-trauma leg runs through a Smith+Nephew distribution agreement signed 2026-02-23; the partner's sales-force prioritisation governs that revenue stream.",
    "iFuse TORQ TNT holds FDA Breakthrough Device status and qualifies for CMS NTAP reimbursement of up to $4,136 per case, a hospital adoption incentive.",
    "Aggregator rating counts in August 2026 show all-Buy coverage with no Hold or Sell, so a first downgrade would be a new event rather than a marginal revision."
  ],
  "body_markdown": "\n-# SIBN — SI-BONE, Inc.\n\n## Current Thesis\n\nThe binary that had been pinning this name resolved on 2026-08-03, and it resolved toward the bulls. Q2 2026 revenue came in at $56.01M, +15.2% YoY, against a $55.335M consensus — an acceleration from the +11.2% posted in Q1 (2026-05-11) — with EPS of −$0.09 versus a −$0.15 estimate, gross margin 79.5%, net loss narrowed to $4.1M and adjusted EBITDA of $2.8M against $1.0M a year earlier. Management lifted the floor of FY2026 revenue guidance to $231–233M from $230–233M (~15–16% growth) and trimmed the operating-expense growth outlook to ~12.0% from ~12.5% at the midpoint. Three firms raised targets the next session (2026-08-04: UBS to $25, Truist to $23, TD Cowen to $20, all Buy). The tape did the corresponding work: the $17.05 shelf that had capped every attempt through June and July is now beneath price, which closed 2026-08-14 at $18.93. The narrative leg an investor is buying is the transition management now describes as a \"spinopelvic\" franchise — SI-joint fusion plus pelvic fixation plus the pelvic-trauma channel opened by the 2026-02-23 Smith+Nephew distribution agreement — carrying mid-teens growth into a first full year of positive adjusted EBITDA. What has changed since the last read is that the growth reacceleration is measured rather than promised. What has not changed is the size of it: this is a ~15% grower still printing GAAP losses, and the next company-dated proof point is roughly three months out.\n\n## Bull Case\n\n- Q2 2026 (2026-08-03): revenue $56.01M, +15.2% YoY, beating the $55.335M consensus; US $53.2M, international $2.8M. Growth accelerated from +11.2% in Q1.\n- EPS −$0.09 versus −$0.15 consensus; net loss narrowed to $4.1M; adjusted EBITDA $2.8M versus $1.0M in Q2 2025 — the profitability slope is now two quarters old, not one.\n- FY2026 guidance floor raised to $231M from $230M (range $231–233M, ~15–16% growth), with operating-expense growth guided down to ~12.0% from ~12.5% and gross margin held at ~79%.\n- Target raises on 2026-08-04 from UBS ($25), Truist ($23) and TD Cowen ($20), all maintaining Buy; Needham has carried the name as a 2026 Top Pick / Conviction List holding with a $27 target.\n- Management framed Q2 growth as broad-based across SI-joint fusion, pelvic fixation and pelvic trauma, attributing it to record physician engagement — i.e. the Smith+Nephew leg is additive rather than cannibalising the core.\n- On the Q2 call management cited finalised and proposed CMS reimbursement changes as reducing hospital and ASC economic barriers for the Granite platform; iFuse TORQ TNT holds FDA Breakthrough Device status with NTAP reimbursement up to $4,136 per case.\n\n## Bear Case\n\n- Management guided Q3 2026 to a 1–2% sequential revenue decline for seasonality and vacation timing. The next reported quarter is expected to be smaller than the one just printed, which removes the sequential-momentum headline for a full cycle.\n- Only the low end of the FY guide moved (from $230M to $231M); the $233M top was left untouched. A double beat that does not raise the ceiling implies the second half embedded in guidance is being met, not exceeded.\n- Shares fell in the after-hours session on 2026-08-03 despite beating on both lines, which locates the disappointment in the outlook rather than the quarter.\n- The company remains GAAP loss-making ($4.1M net loss in Q2) and the adjusted-EBITDA cushion is $2.8M on $56.01M of revenue — thin enough that one soft quarter resets the profitability story.\n- Aggregator rating counts as of August 2026 show all-Buy coverage with no Hold or Sell. There is no upgrade fuel left; the marginal sell-side move from here is downward.\n- The pelvic-trauma leg depends on a partner's sales-force prioritisation. SI-BONE does not control how Smith+Nephew reps allocate their time between iFuse TORQ and the partner's own catalogue.\n\n## Setup & Price Structure\n\nThe structural change is the reclaim. The $17.05 level — resistance for the entire June–July coil, overlapping the 200-day into the print — is now below price after the 2026-08-03 report. The 2026-08-14 close of $18.93 sits 11.5% under the $21.40 52-week high, with a three-month return of +33.7% and RSI(14) at 72.0. That combination is the positioning observable worth naming: the stock is in the overbought band while already having handed back part of the post-print move, so the marginal buyer at $18.93 is paying up after the news and after the target raises. Other crowding markers: three price-target increases clustered into the single session of 2026-08-04; coverage that is uniformly Buy-rated with no Hold; and a run that took the shares out of a $14.13–$17.05 range they occupied for two months. The recent filing record reviewed here shows no insider transactions, so there is no Form 4 evidence either way on selling into the strength.\n\nThe narrative is **accelerating**, dated to 2026-08-03/04 — the growth rate accelerated (11.2% → 15.2%), the guidance floor rose, three targets moved up in one day, and price broke a two-month range. The qualifier is that acceleration in a name of this size is fed by flow, and the next company-dated event is roughly a quarter away; a narrative that has to hold a breakout through a guided sequentially-down quarter with no scheduled headline is the condition under which accelerating rolls to maturing.\n\n## Catalyst Calendar (next 30 days)\n\n- **No confirmed company-dated catalyst falls inside 2026-08-16 → 2026-09-15.** The Q2 print (2026-08-03) and the associated target revisions (2026-08-04) are behind; the window ahead is empty of scheduled company events.\n- **~2026-09 (est.)** — autumn healthcare-conference season (the company has historically presented at bank healthcare conferences in early September). No 2026 date is confirmed on the investor-relations calendar as of this writing; treat any fireside chat as unscheduled headline risk in both directions.\n- **~2026-11-02 (est.)** — Q3 2026 results. The first read against the guided 1–2% sequential decline and the last quarter before the FY2026 revenue guide of $231–233M has to be met.\n\n## Elapsed catalysts\n\n- **~2026-11 (est.)** — CMS calendar-2027 outpatient payment final rule, on the agency's annual cycle. Management tied Granite-platform adoption economics to finalised and proposed CMS changes on the 2026-08-03 call. *(passed 23d ago)*\n\n## What Would Change Our Mind\n\nThe structure to watch is the shelf that was just reclaimed. Losing $17.05 would put the shares back inside the June–July range and would mean the post-print breakout failed to hold its own news — specifically, a weekly close below $17 ends the post-Q2 leg and re-opens the $14.13 floor of the prior coil. Below that, the $11.48 52-week low is the next reference from the 2025–26 downtrend.\n\nOn fundamentals, the thesis-break condition is the Q3 print (est. ~2026-11-02) coming in worse than the guided 1–2% sequential decline, or any narrowing of the $231–233M FY range from the top. A partner-channel stall would show up as management removing pelvic trauma from the list of growth drivers it named in Q2. On flow, the first Hold or Sell initiation, or a target cut from any of the three firms that raised on 2026-08-04, would mark the sell-side as fully spent. And if the shares sit under the $21.40 52-week high for another quarter while the coverage stays wall-to-wall Buy, the classification moves to saturated regardless of what the fundamentals do.\n\n## Correlation Notes\n\n- Small-cap, GAAP-loss medtech: the name trades with the speculative-healthcare complex (XBI, small-cap device peers) and with real-rate direction, more than with the S&P 500. A rate shock compresses this cohort ahead of any company news.\n- Peer read-across runs through spine and orthopedic implant names (Globus Medical, ATEC, Orthofix); a sector-wide procedure-volume or pricing scare pulls SIBN with it even when SI-joint fusion volumes are unaffected.\n- Smith+Nephew (SNN) is the distribution counterparty. SNN commentary on trauma-portfolio prioritisation or sales-force restructuring is a direct input to the pelvic-trauma leg, and SNN reports on its own calendar, not SI-BONE's.\n- Reimbursement is a shared factor with the whole device group: CMS OPPS/IPPS decisions move the hospital-adoption economics for NTAP-eligible products across names at once.\n- Russell 2000 membership means index-flow and small-cap risk appetite act on the tape independently of the fundamental story, particularly around rebalance windows.",
  "first_seen": "2026-06-10",
  "last_analyzed": "2026-08-16T12:09:51+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}